Pulmonary hypertension due to left heart disease: Updated Recommendations of the Cologne Consensus Conference 2011

International Journal of Cardiology

Volumn 154, Issue SUPPL. 1, 2011, Pages

  Rosenkranz, Stephan ^a   Bonderman, Diana ^b   Buerke, Michael ^c   Felgendreher, Ralf ^d   Ten Freyhaus, Henrik ^a   Grünig, Ekkehard ^e   De Haan, Fokko ^f   Hammerstingl, Christoph ^g   Harreuter, Alexander ^h   Hohenforst Schmidt, Wolfgang ⁱ   Kindermann, Ingrid ^j   Kindermann, Michael ^j   Kleber, Franz X ^h   Kuckeland, Matthias ^k   Kuebler, Wolfgang M ^l   Mertens, Dirk ^m   Mitrovic, Veselin ⁿ   Opitz, Christian ^o   Schmeisser, Alexander ^p   Schulz, Uwe ^q   Speich, Rudolf ^r   Zeh, Wolfgang ^s   Weil, Joachim ^t   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d Lippe Detmold Hospital   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Cardiology Practice   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h Ernst von Bergmann Hospital Potsdam   (Germany)

ⁱ KLINIKUM COBURG   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k JO EF STEFAN INSTITUTE   (Slovenia)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁿ KERCKHOFF HEART CENTER   (Germany)

^o DRK Hospital Berlin Köpenick Salvador   (Germany)

^p UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^q RUHR UNIVERSITY BOCHUM   (Germany)

^r UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^s UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^t UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Heart failure, diastolic; Left heart disease; Post capillary PH; Pulmonary hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ILOPROST; INOTROPIC AGENT; NITRATE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; TEZOSENTAN;

BLOOD VESSEL REACTIVITY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DIASTOLIC HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ECHOCARDIOGRAPHY; EUROPE; EVIDENCE BASED PRACTICE; GENETIC LINKAGE; GERMANY; HEALTH CARE PLANNING; HEART CATHETERIZATION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; HEART TRANSPLANTATION; HEART VALVE SURGERY; HUMAN; LEFT HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NORMAL VALUE; PATHOPHYSIOLOGY; PEDIATRIC CARDIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; PULMONOLOGY; SYSTOLIC HEART FAILURE; VALVULAR HEART DISEASE;

GERMANY; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSTAGLANDINS;

EID: 84855395428     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/S0167-5273(11)70491-0     Document Type: Conference Paper

References (64)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219-63.
3. Hoeper MM, Ghofrani HA, Gorenflo M, Grünig E, Schranz D, Rosenkranz S. Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009; Pneumologie 2010;64:401-14.
4. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183-8. (Pubitemid 32051736)
5. Grigioni F, Potena L, Galie N, Fallani F, Bigliardi M, Coccolo F, Magnani G, Manes A, Barbieri A, Fucili A, Magelli C, Branzi A. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant 2006;25:1241-6. (Pubitemid 44528289)
6. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 2007;99:1146-50. (Pubitemid 46578202)
7. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing Z-C, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl S):S43-54.
8. Hoeper M, Barbera JA, Channick R, Hassoun PM, Lang I, Manes A, Martinez F, Naeije R, Olschewski H, Pepke-Zaba J, Redfield M, Robbins I, Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-PAH pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-96.
9. Badesch BD, Champion HC, Gomez-Sanchez MA, Hoeper M, Loyd J, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz R, Torbicki A. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-56.
10. Mc Laughlin VV.Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-1619.
11. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007;28:233-41. (Pubitemid 46350735)
12. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure at rest and exercise in healthy subjects. A systematic review. Eur Respir J 2009;34:888-94.
13. Cappola TP, Felker GM, Kao WH, Hare JM, Baughman KL, Kasper EK. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002;105:1663-8. (Pubitemid 34298609)
14. Davidson CJ, Fishman RF, Bonow RO. Cardiac catheterization. In: Libby P, Bonow RO, Mann DL (eds.): Braunwald's Heart Disease. 8th ed., 2007, pp. 177-203.
15. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit. Circulation 2009;120:992-1007.
16. Morris AH, Chapman RH, Gardner RM. Frequency of technical problems encountered in the measurement of pulmonary artery wedge pressure. Crit Care Med 1984;12:164-70. (Pubitemid 14163284)
17. Gnaegi A, Feihl F, Perret C. Intensive care physicians' insufficient knowledge of right-heart catheterization at the bedside: time to act? Crit Care Med 1997;25:213-20. (Pubitemid 27086052)
18. Jacka MJ, Cohen MM, To T, Devitt JH, Byrick R. Pulmonary artery occlusion pressure estimation: how confident are anesthesiologists? Crit Care Med 2002;30:1197-1203. (Pubitemid 34620958)
19. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009;136:37-43.
20. Delgado JF. The right heart and pulmonary circulation (III): The pulmonary circulation in heart failure. Rev Esp Cardiol 2010;63:334-45.
21. Abramson SV, Burke JF, Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 1992;116:888-95. (Pubitemid 23034779)
22. De Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche JM. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998;32:948-54. (Pubitemid 28459583)
23. Zanchetti A, Cuspidi C, Comarella L, Rosei EA, Ambrosioni E, Chiariello M, Leonetti G, Mancia G, Pessina AC, Salvetti A, Trimarco B, Volpe M, Grassivaro N, Vargiu G. Left ventricular diastolic dysfunction in elderly hypertensives: Results of the APROS-diadys study. J Hypertens 2007;25:2158-67. (Pubitemid 47476315)
24. Kuznetsova T, Herbots L, López B, Jin Y, Richart T, Thijs L, González A, Herregods MC, Fagard RH, Díez J, Staessen JA. Prevalence of left ventricular diastolic dysfunction in the general population. Circ Heart Fail 2009;2:105-12.
25. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, Slama M, Massy Z. Prognosis of heart failure with preserved efection fraction: a 5 year prospective population-based study. Eur Heart J 2008;29:339-47. (Pubitemid 351197754)
26. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;53:1119-26.
27. Faggiano P, Antonini-Canterin F, Ribichini F, et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 2000;85:204-8. (Pubitemid 30026103)
28. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68. (Pubitemid 46276943)
29. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-22.
30. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718-23.
31. Delgado JF, Conde E, Sanchez V, Lopez-Rios F, Gomez-Sanchez MA, Escribano P, Sotelo T, Gomez de la Camara A, Cortina J, de la Calzada CS. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005;7:1011-6. (Pubitemid 41443595)
32. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:615-21.
33. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50. (Pubitemid 47614269)
34. ESC Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG), Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
35. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713.
36. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004;351:1097-1105.
37. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744-50.
38. Chang PP, Longenecker JC, Wang NY, Baughman KL, Conte JV, Hare JM, Kasper EK. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 2005;24:998-1007. (Pubitemid 41127180)
39. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48-54.
40. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92:3593-3612.
41. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006;25:1024-42. (Pubitemid 44311532)
42. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54. (Pubitemid 27329022)
43. Packer M, McMurray J, Massie BM, Caspi A, Charlon V, Cohen-Solal A, Kiowski W, Kostuk W, Krum H, Levine B, Rizzon P, Soler J, Swedberg K, Anderson S, Demets DL. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 2005;11:12-20. (Pubitemid 40215308)
44. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7. (Pubitemid 35245980)
45. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62. (Pubitemid 47511419)
46. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
47. Haraldsson A, Kieler-Jensen N, Ricksten S: The additive pulmonary vasodilator effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001;93:1439-45. (Pubitemid 33111666)
48. Sablotzki A, Czeslick E, Schubert S, et al: Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension. Can J Anaesth 2002; 49:1076-80. (Pubitemid 36231109)
49. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-7. (Pubitemid 36760775)
50. Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003;108:2184-90. (Pubitemid 37363032)
51. Lüscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure (ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-72. (Pubitemid 35364920)
52. Anand I, McMurray J, Cohn JN, et al., EARTH investigators. Long-term effects of darusentan on left ventricular remodeling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:347-54.
53. Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004;94:1475-7. (Pubitemid 39556232)
54. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Cardiac Fail 2008;14:189-197. (Pubitemid 351444866)
55. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115: 59-66. (Pubitemid 46058612)
56. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2339-48. (Pubitemid 39647608)
57. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50:2136-44. (Pubitemid 350117342)
58. Guazzi M, Guazzi MD. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 2008;83:336-41.
59. Abraham WT, Adamson PB, Bourge RC, et al., for the CHAMPION Trial Study Group. Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: A randomized controlled trial. Lancet 2011;377:658-66.
60. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-74.
61. Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX), 2011. Available at: http://www.clinicaltrials.gov.
62. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994;24:982-8. (Pubitemid 24306408)
63. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:238-48. (Pubitemid 47196559)
64. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.